CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03 2024 - 4:10PM
Business Wire
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a
leading precision medicine company focused on the discovery,
development, and commercialization of clinically differentiated,
high-value healthcare solutions for transplant patients and
caregivers — today announced that, as an inducement material to
entering into employment with CareDx, on April 19, 2024, 17 new
employees were awarded restricted stock units (RSUs) for an
aggregate of 54,350 shares of common stock. The RSUs were granted
pursuant to the Company’s 2019 Inducement Equity Incentive Plan,
which was approved by the Compensation Committee of the Board of
Directors in August 2019 under Nasdaq Listing Rule 5635(c)(4).
RSUs for an aggregate of 43,350 shares vest over four years,
with 25% of the RSUs vesting on the first anniversary of the
applicable vesting commencement date, and the balance vesting
annually thereafter in three equal installments, subject to the
grantee’s continued service through each applicable vesting date.
RSUs for an aggregate of 8,000 shares vest over three years, with
33.33% of the RSUs vesting on the first anniversary of the
applicable vesting commencement date, and the balance vesting
quarterly over two years thereafter, subject to the grantee’s
continued service through each applicable vesting date. RSUs for
1,000 shares vest over two years, with 50% of the RSUs vesting on
each of the first two anniversaries of the applicable vesting
commencement date, subject to the grantee’s continued service
through each applicable vesting date. RSUs for 2,000 shares vest on
the one-year anniversary of the applicable vesting commencement
date, subject to the grantee’s continued service through such
date.
CareDx is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the equity grants.
These forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including general economic and market
factors; and other risks discussed in CareDx’s filings with the
SEC, including the Annual Report on Form 10-K for the fiscal year
ended December 31, 2023 filed by CareDx with the SEC on February
28, 2024, and other reports that CareDx has filed with the SEC. Any
of these may cause CareDx’s actual results, performance, or
achievements to differ materially and adversely from those
anticipated or implied by CareDx’s forward-looking statements.
CareDx expressly disclaims any obligation, except as required by
law, or undertaking to update or revise any such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503241982/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2024 to May 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From May 2023 to May 2024